Kim Kyu Young, Jeon Seong Woo, Park Jung Gil, Yu Chung Hoon, Jang Se Young, Lee Jae Kwang, Hwang Hee Young
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Ann Coloproctol. 2014 Aug;30(4):201-4. doi: 10.3393/ac.2014.30.4.201. Epub 2014 Aug 26.
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder characterized by hundreds of colorectal adenomatous polyps that progress to colorectal cancer. Management of patients with FAP is with a total colectomy. Chemopreventive strategies have been studied in FAP patients in an effort to delay the development of adenomas in the upper and the lower gastrointestinal tract and to prevent recurrence of adenomas in the retained rectum of patients after prophylactic surgery. Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients. However, evidence regarding long-term use of this therapy and its effect on the intact colon has been insufficient. We report a case in which the long-term use of sulindac was effective in reducing the size and the number of colonic polyps in patients with FAP without a prophylactic colectomy and polypectomy; we also present a review of the literature.
家族性腺瘤性息肉病(FAP)是一种常染色体显性疾病,其特征为数百个结肠腺瘤性息肉,这些息肉会发展为结肠癌。FAP患者的治疗方法是全结肠切除术。为了延缓上、下消化道腺瘤的发展,并预防预防性手术后患者保留直肠内腺瘤的复发,已对FAP患者的化学预防策略进行了研究。舒林酸是一种非甾体抗炎药,可使FAP患者保留直肠段的结肠腺瘤消退。然而,关于长期使用这种疗法及其对完整结肠的影响的证据一直不足。我们报告了一例长期使用舒林酸有效减少未进行预防性结肠切除术和息肉切除术的FAP患者结肠息肉大小和数量的病例;我们还对相关文献进行了综述。